Prevalence of Frailty Assessed by Fried and Kihon Checklist Indexes in a Prospective Cohort Study: Design and Demographics of the Kyoto-Kameoka Longitudinal Study

2017 ◽  
Vol 18 (8) ◽  
pp. 733.e7-733.e15 ◽  
Author(s):  
Yosuke Yamada ◽  
Hinako Nanri ◽  
Yuya Watanabe ◽  
Tsukasa Yoshida ◽  
Keiichi Yokoyama ◽  
...  
Keyword(s):  
Cohort Study ◽  
Longitudinal Study ◽  
Prospective Cohort Study ◽  
Study Design ◽  
Prospective Cohort ◽  
Cohort Study Design

Fine or Gross Motor Index as a Simple Tool for Predicting Cognitive Impairment in Elderly People: Findings from The Irish Longitudinal Study on Ageing (TILDA)

2021 ◽  
pp. 1-8
Author(s):  
Xiao Liu ◽  
Ayiguli Abudukeremu ◽  
Yuan Jiang ◽  
Zhengyu Cao ◽  
Maoxiong Wu ◽  
...  
Keyword(s):  
Cohort Study ◽  
Cognitive Impairment ◽  
Longitudinal Study ◽  
Cognitive Function ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Simple Tool

Background: Several kinds of motor dysfunction can predict future cognitive impairment in elderly individuals. However, the ability of the fine motor index (FINEA) and gross motor index (GROSSA) to predict the risk of cognitive impairment has not been assessed. Objective: We investigated the associations between FINEA/GROSSA and cognitive impairment. Methods: The data of 4,745 participants from The Irish Longitudinal Study on Ageing (TILDA) were analyzed. Cognitive function was assessed using the Mini-Mental State Examination (MMSE). We first assessed the correlation between the FINEA GROSSA and MMSE in a cross-sectional study. Then, we further investigated the predictive role of the incidence of cognitive impairment in a prospective cohort study. Results: We found that both FINEA and GROSSA were negatively correlated with MMSE in both the unadjusted (FINEA: B = –1.00, 95%confidence intervals (CI): –1.17, –0.83, t = –11.53, p <  0.001; GROSSA: B = –0.85, 95%CI: –0.94, –0.76, t = –18.29, p <  0.001) and adjusted (FINEA: B = –0.63, 95%CI: –0.79, –0.47, t = –7.77, p <  0.001; GROSSA: B = –0.57, 95%CI: –0.66, –0.48, t = –12.61, p <  0.001) analyses in a cross-sectional study. In a prospective cohort study, both high FINEA and high GROSSA were associated with an increased incidence of cognitive function impairment (FINEA: adjusted odds ratios (OR) = 2.35, 95%CI: 1.05, 5.23, p = 0.036; GROSSA adjusted OR = 3.00, 95%CI: 1.49, 6.03, p = 0.002) after 2 years of follow-up. Conclusion: Higher FINEA and GROSSA scores were both associated with an increased incidence of cognitive impairment. FINEA or GROSSA might be a simple tool for identifying patients with cognitive impairment.

scholarly journals SALGOT - Stroke Arm Longitudinal study at the University of Gothenburg, prospective cohort study protocol

BMC Neurology ◽  
2011 ◽  
Vol 11 (1) ◽  
Author(s):  
Margit Alt Murphy ◽  
Hanna C Persson ◽  
Anna Danielsson ◽  
Jurgen Broeren ◽  
Åsa Lundgren-Nilsson ◽  
...  
Keyword(s):  
Cohort Study ◽  
Longitudinal Study ◽  
Prospective Cohort Study ◽  
Study Protocol ◽  
Prospective Cohort ◽  
The University

Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9138-9138 ◽  
Author(s):  
Julie Lemieux ◽  
Elizabeth Maunsell ◽  
Louise Provencher ◽  
Sophie Lauzier ◽  
Rami Younan ◽  
...  
Keyword(s):  
Cohort Study ◽  
Prospective Cohort Study ◽  
Prospective Cohort ◽  
Safety Data ◽  
Quebec City ◽  
Scalp Cooling ◽  
Cohort Study Design ◽  
Eortc Qlq C30 ◽  
Table Data ◽  
Eortc Qlq

9138 Background: Scalp cooling can prevent chemotherapy-induced alopecia. Success varies according to the type of chemotherapy. A controversy exists regarding the use of scalp cooling because of the lack of efficacy data with modern chemotherapy regimen and safety data. We present a prospective cohort study design to measure alopecia. Methods: The prospective study was conducted at the Centre des Maladies du Sein Deschênes-Fabia (CMS) in Quebec City (where scalp cooling is offered routinely and 85% of women use it) and at the Centre Hospitalier Universitaire de Montreal (CHUM), in Montreal (where scalp cooling is not available). Women were eligible if they were going to receive neoadjuvant or adjuvant chemotherapy for breast cancer. The study involved completion of questionnaires (on degree of alopecia, hair type, hair care, use of head accessories, tolerance to scalp cooling and questions related to sick leave from work) and having pictures taken at baseline, cycle 3 and at the last cycle of chemotherapy. For the last 43 patients, the EORTC QLQ-C30/BR23 and an adaptation for Hairdex were added. Results: A total of 136 patients were recruited (110 at CMS over 2 years and 26 at the CHUM over a 9-month period). Preliminary efficacy results are shown in the Table (data on quality of life have not yet been analyzed). Hair preservation was defined as a SUCCESS for hair loss (since the beginning of chemotherapy) characterized as “not at all”, “a little” or “moderate” and “FAILURE” when characterized as “a lot” or “all” or “hair shaved”. Overall, in the scalp cooling group, 34% were considered a “success” using hairdresser evaluation and 49% using patient evaluation; for the non scalp-cooling group, these rates were 9% and 4% respectively. Conclusions: Scalp cooling appears to be efficacious for preventing chemotherapy-induced alopecia in this exploratory cohort study. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document